Introduction: The dual burden of TB and DM has emerged as a critical public health concern. Diabetes is associated with a twofold increase in the risk of developing TB, leading to poorer treatment outcomes and higher mortality rates. Conversely, TB exacerbates glycemic control in diabetic patients, creating a vicious cycle that complicates management. Globally, the rising prevalence of DM in TB-endemic regions underscores the urgency of addressing this co-morbidity.

Case Series: The presented case series includes six patients (two male and four female) from a tertiary care center, highlighting the interaction of TB and DM across various clinical scenarios:

Male Patients

1. Patient 1: A 34-year-old male with pulmonary TB (PTB) for four years and DM for an equal duration. Despite treatment with metformin and glimepiride, his glycemic control remained poor (HGT 268 mg/dL). GeneXpert testing showed no detectable TB, and HIV was non-reactive.

2. Patient 2: A 72-year-old male with PTB for 1.5 years and newly diagnosed DM. Glycemic control was managed with plain insulin, but fasting blood sugar (FBS) remained critically high (546 mg/dL). GeneXpert revealed rifampicin-sensitive MTB, and HIV testing was non-reactive.

Female Patients:

1. Patient 1: A 50-year-old female with PTB and gross pleural effusion managed with an intercostal drain. Diagnosed with DM three months ago, she was on metformin and glimepiride but exhibited elevated HGT (221 mg/dL). Sputum GeneXpert and fluid cytology results were pending.

2. Patient 2: A 32-year-old female with PTB for one month and DM managed with insulin (6-6-6). GeneXpert detected rifampicin-sensitive MTB.

3. Patient 3: A 51-year-old female with PTB for one month and an eight-year history of DM. Despite treatment with glynase MF, glycemic control was suboptimal. No TB culture growth was noted, and HIV was non-reactive.

4. Patient 4: A 32-year-old female with PTB on Category I therapy. Longstanding DM (HbA1c: 12.2%) was managed with insulin (12-12-10). GeneXpert and LPA confirmed rifampicin and isoniazid-sensitive MTB.

Discussion

Interplay Between TB and Diabetes

The co-morbidity of TB and DM creates a reciprocal influence, where diabetes increases susceptibility to TB and complicates its course, while TB exacerbates glycemic control. Diabetic patients often present with atypical TB symptoms, delayed sputum conversion, and higher rates of drug-resistant TB.

Diagnostic Challenges

1. Latent TB in Diabetics: High-risk populations necessitate enhanced screening, utilizing tools such as IGRA and TST.

2. Hyperglycemia's Impact on TB Diagnosis: Poor glycemic control may mask or modify TB symptoms, complicating the diagnostic process.

Treatment Complexity

1. Drug Interactions: Managing TB-DM co-morbidity often involves adjusting anti-TB regimens to avoid interactions with hypoglycemic agents.

2. Prolonged Therapy: Diabetic patients frequently require extended TB treatment durations to prevent relapse.

3. Adherence Challenges: Dual therapy increases the burden on patients, necessitating robust counseling and support systems.

Integrated Care Strategies

Coordinated Screening: Joint protocols for TB and DM screening in high-risk populations.

Multidisciplinary Teams: Collaboration between pulmonologists, endocrinologists, and primary care providers.

Public Health Interventions: Strengthening healthcare systems to address the dual burden through education, surveillance, and policy reforms.